Couldn't find a thread to put this in, so apologies for starting a new one.
There is a large annual meeting of the International Society for Gene and Cell Therapy tonight. There will clearly be discussions on MSc stem-cells with Dr Marks particularly of the FDA at the convention:
https://www.isctglobal.org/home
If you are interested in the science and the regulatory reception, there could be some useful insights.
Certainly some dicsussion of MSc potency assays and mechanisms of action that could be very pertinent to CYP's trial in C-19 ARDS particularly (and MSB of course).
As I posted on MSB, there was a rather unheralded but crucial paper recently published on MSc mechanisms of actions in humans, the first of its kind. This rather addresses some of the concerns coming from the FDA regards these treatments and no doubt the TGA in Australia:
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-021-02862-x
- Forums
- ASX - By Stock
- CYP
- Stem Cell News
Stem Cell News
- There are more pages in this discussion • 514 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CYP (ASX) to my watchlist
(20min delay)
|
|||||
Last
23.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $42.21M |
Open | High | Low | Value | Volume |
22.0¢ | 23.5¢ | 22.0¢ | $20.38K | 90.67K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 86380 | 21.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
23.5¢ | 12372 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 86380 | 0.210 |
4 | 165257 | 0.200 |
2 | 13135 | 0.195 |
1 | 30000 | 0.190 |
3 | 102017 | 0.185 |
Price($) | Vol. | No. |
---|---|---|
0.235 | 12372 | 2 |
0.240 | 91350 | 1 |
0.245 | 10000 | 1 |
0.250 | 42019 | 2 |
0.275 | 21895 | 1 |
Last trade - 16.10pm 09/05/2024 (20 minute delay) ? |
|
|||||
Last
23.0¢ |
  |
Change
0.000 ( 2.22 %) |
|||
Open | High | Low | Volume | ||
23.0¢ | 23.0¢ | 23.0¢ | 10474 | ||
Last updated 11.40am 09/05/2024 ? |
Featured News
CYP (ASX) Chart |